BIOTYPE launches MODAPLEX platform upgrade for multi-gene testing

Germany-based diagnostic company BIOTYPE has launched a major upgrade of its MODAPLEX platform. The benchtop diagnostic platform for the fully integrated analysis of molecular biomarker signatures allows laboratories in research and clinical settings to perform highly specialised molecular analyses quickly and easily in an automated manner.

The compact and powerful MODAPLEX technology means the most important decision-relevant biomarkers can be detected and evaluated simultaneously in a few simple steps. For more than ten years, the Dresden-based molecular diagnostics company has been investing in the development, production, and marketing of molecular test systems for the detection of disease-relevant genetic alterations. Now, BIOTYPE is launching the next generation of its hardware platform by simplifying the software for automated data analysis for the detection and quantification of cancer-related RNA and DNA biomarkers.

The MODAPLEX platform is an open system solution, with BIOTYPE enabings third parties, such as molecular testing system manufacturers or pharmaceutical companies, to develop and market their own assays. This approach expands the market of available tests and increases the attractiveness of MODAPLEX for users who wish to obtain their test kits from multiple sources.

"The launch of the next-generation MODAPLEX system also marks our entry into the international business for molecular testing platforms," said BIOTYPE CEO Dr Norman Gerstner. "Last year, we repositioned the company in the rapidly growing precision medicine market. In addition to molecular tests for highly specialised diagnostics of complex diseases, we are now expanding our portfolio to include software and instruments. "

In addition, MODAPLEX is making an important contribution to meeting the growing demand for sophisticated technologies for multi-gene testing. In less than four hours, the automated workflow of the MODAPLEX platform delivers fast and accurate results to pathologists and clinicians. Decision-relevant RNA and DNA biomarkers are measured simultaneously from a single sample. On this basis, the best possible therapy can be initiated.


Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

The British Association for Cytopathology Annual Scientific Meeting

Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024